GH Research PLC (GHRS)Healthcare | Biotechnology | Dublin, Ireland | NasdaqGM
18.34 USD
+0.60
(3.382%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 18.73 +0.39 (2.126%) ⇧ (April 17, 2026, 7:58 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:50 p.m. EDT
GH Research PLC (GHRS) is experiencing mixed signals in the short term with recent news about clinical progress and a moderate buy consensus, which could indicate some optimism. However, the stock has been volatile and is currently trading above its 50-day average, suggesting possible overbought conditions. The lack of dividend payouts and negative earnings suggest caution for long-term investors. While the options market shows some activity, it is not enough to indicate a strong directional bias. Overall, GHRS appears to be a speculative opportunity with potential for short-term gains, but it carries significant risk and should be approached with caution. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.057709 |
| AutoARIMA | 0.068726 |
| AutoETS | 0.070185 |
| AutoTheta | 0.083072 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 4.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.264 |
| Excess Kurtosis | 0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.183 |
| Market Cap | 1,137,619,072 |
| Forward P/E | -9.99 |
| Beta | 1.00 |
| Website | https://www.ghres.com |
As of April 11, 2026, 3:50 p.m. EDT: Options speculators are showing mixed signals. For the April 17 expiration, there is a notable amount of open interest (OI) and volume on both calls and puts, especially around the 12.5 and 15.0 strike prices, indicating potential for short-term volatility. The ATM IV for calls is higher than puts, suggesting some bullish sentiment, but the overall activity is limited. For July 17, the OI and volume are lower, with more focus on the 17.5 and 20.0 strike prices. The October 16 options show higher OI on puts around the 12.5 strike, which could imply a bearish outlook for the short term. The overall options activity suggests a cautious approach with potential for short-term price movements, but not a clear directional bias.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0 |
| Address1 | Joshua Dawson House |
| Address2 | Dawson Street |
| All Time High | 30.43 |
| All Time Low | 5.05 |
| Ask | 18.48 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 117,230 |
| Average Daily Volume3 Month | 196,120 |
| Average Volume | 196,120 |
| Average Volume10Days | 117,230 |
| Beta | 1.003 |
| Bid | 18.11 |
| Bid Size | 1 |
| Book Value | 4.509 |
| City | Dublin |
| Country | Ireland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.34 |
| Current Ratio | 34.126 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 18.6999 |
| Day Low | 17.64 |
| Debt To Equity | 0.183 |
| Display Name | GH Research |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -60,599,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.149 |
| Enterprise Value | 857,423,104 |
| Eps Current Year | -1.32429 |
| Eps Forward | -1.83571 |
| Eps Trailing Twelve Months | -0.79 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.2136 |
| Fifty Day Average Change | 3.1264 |
| Fifty Day Average Change Percent | 0.20550033 |
| Fifty Two Week Change Percent | 100.0 |
| Fifty Two Week High | 19.51 |
| Fifty Two Week High Change | -1.1700001 |
| Fifty Two Week High Change Percent | -0.05996925 |
| Fifty Two Week Low | 8.663 |
| Fifty Two Week Low Change | 9.677 |
| Fifty Two Week Low Change Percent | 1.1170495 |
| Fifty Two Week Range | 8.663 - 19.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,627,800,000 |
| Float Shares | 22,816,272 |
| Forward Eps | -1.83571 |
| Forward P E | -9.9906845 |
| Free Cashflow | -30,543,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 73 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.26775998 |
| Held Percent Institutions | 0.74932 |
| Implied Shares Outstanding | 62,029,395 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. |
| Long Name | GH Research PLC |
| Market | us_market |
| Market Cap | 1,137,619,072 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_707594028 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -48,258,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,132,656,752 |
| Number Of Analyst Opinions | 8 |
| Open | 17.85 |
| Operating Cashflow | -43,552,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 353 1 437 8334 |
| Post Market Change | 0.3899994 |
| Post Market Change Percent | 2.126496 |
| Post Market Price | 18.73 |
| Post Market Time | 1,776,470,285 |
| Previous Close | 17.74 |
| Price Eps Current Year | -13.84893 |
| Price Hint | 2 |
| Price To Book | 4.067421 |
| Profit Margins | 0.0 |
| Quick Ratio | 33.652 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.6 |
| Regular Market Change Percent | 3.38219 |
| Regular Market Day High | 18.6999 |
| Regular Market Day Low | 17.64 |
| Regular Market Day Range | 17.64 - 18.6999 |
| Regular Market Open | 17.85 |
| Regular Market Previous Close | 17.74 |
| Regular Market Price | 18.34 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 138,502 |
| Return On Assets | -0.15917 |
| Return On Equity | -0.21043 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 62,029,395 |
| Shares Percent Shares Out | 0.0357 |
| Shares Short | 2,214,414 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,703,885 |
| Short Name | GH Research PLC |
| Short Percent Of Float | 0.1091 |
| Short Ratio | 9.82 |
| Source Interval | 15 |
| Symbol | GHRS |
| Target High Price | 70.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 39.25 |
| Target Median Price | 36.5 |
| Total Cash | 280,708,000 |
| Total Cash Per Share | 4.525 |
| Total Debt | 512,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.79 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.409875 |
| Two Hundred Day Average Change | 3.9301252 |
| Two Hundred Day Average Change Percent | 0.27273834 |
| Type Disp | Equity |
| Volume | 138,502 |
| Website | https://www.ghres.com |
| Zip | D02 RY95 |